Epic Sciences, based in San Diego, CA, is a leading provider of comprehensive cancer profiling solutions. Their innovative technology utilizes a multi-technology approach, including CTC capabilities, ctDNA, and immune-cell analysis, to provide clinicians and drug development professionals with valuable insights for prostate and breast cancer. With personalized, predictive, and proven tests, Epic Sciences empowers cancer patients and their physicians to make informed decisions about the most effective course of therapy.
Through their groundbreaking liquid biopsy platform, Epic Sciences is able to detect rare cells that others may miss, offering a deeper understanding of both genotype and phenotypes. Their AR-V7 test, the first and only CTC-based liquid-biopsy test reimbursed by Medicare, provides clinically-validated results for men with metastatic castration-resistant prostate cancer. Additionally, Epic Sciences collaborates with pharmaceutical and clinical investigation partners to develop unbiased cancer research solutions that enhance drug development and provide valuable insights into the dynamics of cancer growth and evolution.
Generated from the website